Search
Dabrafenib
go.drugbank.com/drugs/DB08912ApprovedInvestigational[L41955] It was also used for metastatic non-small cell lung cancer with the same mutation. … [L41955] In May 2018, Tafinlar (dabrafenib), in combination with Mekinist ([DB08911]), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.[L41955]
Isavuconazonium
go.drugbank.com/drugs/DB06636ApprovedInvestigational[A6913,A6914,A262706] On December 08, 2023, the FDA approved the expanded use of isovuconazonium in pediatric patients for the same indications.[L49251] … , marketed by Astellas under the brand Cresemba.
Bevacizumab
go.drugbank.com/drugs/DB00112ApprovedInvestigational[A286054] This off-label practice was formalized with the approval of Lytenava (bevacizumab-vikg in the US; bevacizumab gamma in the EU/UK), the first ophthalmic formulation of bevacizumab developed specifically … [A192888,A192939] The same anti-VEGF activity that suppresses tumor angiogenesis also suppresses the pathological choroidal and retinal neovascularization that drives vision loss in retinal disease, giving
Ustekinumab
go.drugbank.com/drugs/DB05679ApprovedInvestigationalIn October 2019, it was also approved by the FDA for use to manage moderately to severely active ulcerative colitis in adults. … [A187346] The therapeutic use of the drug started in Canada, the US, and Europe since 2009 when it was first approved for the treatment of adult patients with moderate to severe plaque psoriasis and
Trofinetide
go.drugbank.com/drugs/DB06045Approved[A258438] Trofinetide was approved by the FDA on March 10, 2023, for the treatment of Rett syndrome,[L45718,L45748] which is an X-linked neurodevelopmental disorder characterized by a range of cognitive … [A258438] Trofinetide is believed to work by reducing inflammation and apoptosis of neurons.
Pegzilarginase
go.drugbank.com/drugs/DB14780ApprovedFDA in February 2026 for the treatment of hyperargininemia in adult and pediatric patients aged 2 years and older with ARG1-D, to be used in conjunction with dietary protein restriction. … [L56053] By substituting the native manganese cofactor with cobalt to enhance catalytic activity, this agent effectively degrades elevated plasma arginine into ornithine and urea, thereby mitigating the
Lauric acid
go.drugbank.com/drugs/DB03017ApprovedLauric acid is an inexpensive, non-toxic and safe to handle compound often used in laboratory investigations of melting-point depression. … Lauric acid is a solid at room temperature but melts easily in boiling water, so liquid lauric acid can be treated with various solutes and used to determine their molecular masses.
Fluconazole
go.drugbank.com/drugs/DB00196ApprovedInvestigationalIt was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole].
Products: FLUCONAZOL MK 50 MG CÁPSULAS, FLUCONAZOL MK 2 MG/ML SOLUCION I.VSecukinumab
go.drugbank.com/drugs/DB09029ApprovedInvestigational[A249840] Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). … [L39600] By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders.
Neomycin
go.drugbank.com/drugs/DB00994ApprovedInvestigationalVet approved[A175042] Neomycin is active against both gram-positive and gram-negative organisms and mediates its pharmacological action by binding to bacterial ribosomes and inhibiting protein synthesis, which is … also used in combination with [polymyxin B] sulfates and [hydrocortisone] in otic suspensions for use in the treatment of bacterial infections in the external auditory canal, including infections caused by
Mixtures: Johnson and Johnson Safe Travels First Aid Kit, Bus and Classroom Yellow